The short answer
Bjerre Knudsen and colleagues reported in Endocrinology in 2010 that GLP-1 receptor agonists activate rodent thyroid C-cells, causing calcitonin release and C-cell proliferation. That finding, replicated and characterised as on-target, is the origin of the boxed warning.
Key facts
- Foundational paper
- Bjerre Knudsen 2010, Endocrinology
- PMID
- 20203154
- Species
- Rats and mice
- Observed
- Calcitonin release, C-cell proliferation
- Characterisation
- On-target, receptor-mediated
- Follow-up
- Rosol 2013, Toxicol Pathol (PMID 23471186)
What C-cells are
Parafollicular cells in the thyroid that produce calcitonin, a hormone involved in calcium handling. They are a minority population and distinct from the follicular cells that make thyroid hormone, which is why medullary thyroid carcinoma, arising from C-cells, is a different disease from the far commoner papillary and follicular thyroid cancers.
What was observed
In rats and mice given GLP-1 receptor agonists, C-cells released calcitonin and proliferated. With sustained exposure this progressed to C-cell hyperplasia and, in some animals, to tumours. The 2010 Endocrinology paper established the sequence rather than merely reporting an endpoint, which is what made it persuasive.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why on-target is the important descriptor
Rosol and colleagues characterised these as on-target effects in Toxicologic Pathology in 2013. On-target means the effect proceeds through the intended receptor rather than through an unrelated interaction or a contaminant. That makes it a predictable consequence of the pharmacology in that species. It also means the effect should be expected wherever the receptor is present at sufficient density, which becomes the crux of the human question.
Why regulators acted on a rodent finding
Because a receptor-mediated proliferative effect in two species is a serious signal, and medullary thyroid carcinoma is a condition where caution is cheap relative to the consequence. The resulting boxed warning contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
The question the rodent work raises but cannot answer
Whether human C-cells behave the same way. An on-target effect depends on the target being present, and receptor expression differs between species more often than is assumed. That question was addressed directly by later work, and the answer is not what a straightforward reading of the rodent data would predict.
What this concerns
Licensed medicines assessed by regulators, and toxicology conducted under regulated conditions. Nothing supplied on this site is a GLP-1 receptor agonist, and none of this literature describes anything sold here.
Frequently asked questions
What did the rodent studies show?
GLP-1 receptor agonists activated thyroid C-cells in rats and mice, causing calcitonin release and proliferation, progressing to hyperplasia and in some animals tumours.
What does 'on-target' mean?
That the effect proceeds through the intended receptor rather than an unrelated interaction, making it a predictable consequence of the pharmacology in that species.
What does the boxed warning say?
It contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedBjerre Knudsen L et al., Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010 (PMID 20203154)pubmed.ncbi.nlm.nih.gov
- PubMedRosol TJ, On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicol Pathol 2013 (PMID 23471186)pubmed.ncbi.nlm.nih.gov
- PubMedWaser B et al., Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans. Neuroendocrinology 2011 (PMID 21893952)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Normal Human Thyroid Has No Detectable GLP-1 ReceptorsWaser 2011 measured incretin receptors in rodent and human thyroid. The species difference is stark - and the human receptor picture points at GIP, not GLP-1.
- The Strongest Warning a Label CarriesA boxed warning is the most serious labelling a regulator applies. It does not mean a risk is proven - it means the consequence would be severe.
- The Hormone That Empties the Gallbladder, SuppressedCholecystokinin makes the gallbladder contract. GLP-1 suppresses cholecystokinin secretion - which is the identified mechanism behind the biliary events.
- What the Meta-Analysis EstablishedHe 2022 pooled randomised trials on gallbladder and biliary disease with GLP-1 receptor agonists. Why pooling was necessary for an outcome this infrequent.
- The Gallbladder Case Is Unusually CompleteObservation, then mechanism, then quantification. Most safety signals never get all three - which is why this one is worth studying as a template.